FDA Grants Historic Approval to Filspari for Rare Kidney Disease FSGS WASHINGTON — In a watershed moment for nephrology, the U.S. Food and Drug Administration (FDA) has granted approval to Filspari, marking the first-ever approved pharmacological treatment for focal segmental glomerulosclerosis (FSGS). Developed by Travere Therapeutics, the medication represents a critical breakthrough for patients battling … Read more
For decades, the blueprint of modern medicine has been drawn using a dangerously narrow set of data. While genomic research has accelerated the treatment of chronic diseases globally, the vast majority of this data has been derived from populations of European descent, leaving a critical “genomic gap” for the world’s most genetically diverse continent: Africa. … Read more
A significant breakthrough in understanding IgA nephropathy – a leading cause of kidney disease – has emerged from research at Fujita Health University in Japan. Scientists have identified complement factor H-related protein 1 (CFHR1) as a key player in the disease’s progression, offering a potential new diagnostic marker and opening doors for targeted therapies. This … Read more
The complexities of managing chronic kidney disease (CKD) extend far beyond the mechanics of dialysis. A growing body of research, synthesized from recent publications (Flythe & Watnick, 2024; Cozzolino et al., 2018), highlights the critical interplay between physiological demands, psychological well-being, and adherence to treatment protocols – particularly fluid and dietary restrictions. This isn’t simply … Read more